Director James Huang Buys $371K in Open Market Shares
CNTB has more than doubled off its 52-week low of $0.73.
Summary
Director James Huang made an open market purchase of $371,610 worth of Connect Biopharma ordinary shares, continuing a trend of insider accumulation.
Key Events · Ownership and Investor Activity · CNTB
-
Director Open Market Purchase
Director James Huang acquired 150,000 ordinary shares for $371,610 at a weighted average price of $2.48 per share on May 29, 2026.
-
Continued Insider Accumulation
This purchase follows a larger $4.0 million acquisition by Director Huang in early April, indicating sustained insider belief in the company's prospects.
-
Post-Transaction Holdings
Following this transaction, James Huang's indirect holdings total 13,310,000 shares.
Analysis · CNTB · Life Sciences
This open market purchase by Director James Huang, following a larger $4.0 million acquisition in early April, indicates continued insider confidence in Connect Biopharma. The transaction occurred after recent positive Phase 3 trial results and a significant private placement, suggesting the director sees further upside despite the company's recent financial performance.
At the time of this filing, CNTB was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $135.4M. The 52-week trading range was $0.73 to $3.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.